Literature DB >> 26682841

Under seize: neurocysticercosis in an immigrant woman and review of a growing neglected disease.

Meredith Bock1, Hector H Garcia2, Peter Chin-Hong3, Sanjiv M Baxi4.   

Abstract

Neurocysticercosis (NCC) is a significantly neglected tropical disease and, with increasing globalisation, a notable emerging infection in the developed world. We describe a case of ventricular NCC in a 22-year-old Mexican-American woman with a history of seizures, who presented with 2 weeks of headaches and intermittent fevers progressing to altered mental status and vomiting. Initial imaging revealed a cystic mass at the posteroinferior aspect of the third ventricle superior to the aqueduct of Sylvius, calcifications scattered throughout the parenchyma, and enlargement of the lateral and third ventricles. Initial laboratories were unrevealing and serum investigations for Taenia solium antibody were negative, but T. solium antibody was subsequently returned positive from cerebrospinal fluid. This case highlights important issues regarding the clinical presentation, diagnostic evaluation and treatment of NCC relevant to providers not only in areas with endemic disease but, importantly, in locales with diverse immigrant populations. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26682841      PMCID: PMC4691866          DOI: 10.1136/bcr-2015-212839

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  30 in total

1.  Neurocysticercosis: is serology useful in the absence of brain imaging?

Authors:  Hector H Garcia; Silvia Rodriguez; Robert H Gilman; Armando E Gonzalez; Victor C W Tsang
Journal:  Trop Med Int Health       Date:  2012-07-19       Impact factor: 2.622

2.  A diagnostic and therapeutic scheme for a solitary cysticercus granuloma.

Authors:  G Singh; V Rajshekhar; J M K Murthy; S Prabhakar; M Modi; N Khandelwal; H H Garcia
Journal:  Neurology       Date:  2010-12-14       Impact factor: 9.910

Review 3.  Corticosteroid use in neurocysticercosis.

Authors:  Theodore E Nash; Siddhartha Mahanty; Hector H Garcia
Journal:  Expert Rev Neurother       Date:  2011-08       Impact factor: 4.618

Review 4.  Neurocysticercosis in Western Europe: a re-emerging disease?

Authors:  Oscar H Del Brutto
Journal:  Acta Neurol Belg       Date:  2012-04-18       Impact factor: 2.396

5.  Conformation-sensitive immunoassays improve the serodiagnosis of solitary cysticercus granuloma in Indian patients.

Authors:  Vasudevan Prabhakaran; Vedantam Rajshekhar; Kenneth Darwin Murrell; Anna Oommen
Journal:  Trans R Soc Trop Med Hyg       Date:  2006-12-13       Impact factor: 2.184

6.  Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.

Authors:  Hector H Garcia; Isidro Gonzales; Andres G Lescano; Javier A Bustos; Mirko Zimic; Diego Escalante; Herbert Saavedra; Martin Gavidia; Lourdes Rodriguez; Enrique Najar; Hugo Umeres; E Javier Pretell
Journal:  Lancet Infect Dis       Date:  2014-07-03       Impact factor: 25.071

7.  Contemporary neurosurgical approaches to neurocysticercosis.

Authors:  Leonardo Rangel-Castilla; Jose A Serpa; Shankar P Gopinath; Edward A Graviss; Pedro Diaz-Marchan; A Clinton White
Journal:  Am J Trop Med Hyg       Date:  2009-03       Impact factor: 2.345

Review 8.  Imaging findings in neurocysticercosis.

Authors:  Héctor H García; Oscar H Del Brutto
Journal:  Acta Trop       Date:  2003-06       Impact factor: 3.112

Review 9.  Epidemiology and management of cysticercosis and Taenia solium taeniasis in Europe, systematic review 1990-2011.

Authors:  Lorenzo Zammarchi; Marianne Strohmeyer; Filippo Bartalesi; Elisa Bruno; José Muñoz; Dora Buonfrate; Alessandra Nicoletti; Héctor Hugo García; Edoardo Pozio; Alessandro Bartoloni
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

10.  Public health implications of cysticercosis acquired in the United States.

Authors:  Frank Sorvillo; Patricia Wilkins; Shira Shafir; Mark Eberhard
Journal:  Emerg Infect Dis       Date:  2011-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.